Dublin, June 14, 2024 (GLOBE NEWSWIRE) -- The "CAR-T Therapy - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering.
This report provides in-depth insights into the CAR-T therapy pipeline, revealing extensive research and development activities in this dynamic field. The report showcases the collective efforts of over 200 companies with more than 252 pipeline drugs at various stages of clinical and nonclinical development. This report is foundational for understanding the current landscape and future directions of CAR-T therapy innovation.
Advanced Therapeutic Development
With the aim of revolutionizing cancer treatment, the report emphasizes the advancements in CAR-T therapy - a form of immunotherapy where T cells are genetically engineered to better recognize and combat cancer cells. It highlights efforts to overcome current technological limitations, enhance safety profiles, and explore novel applications beyond oncology, including autoimmune and inflammatory diseases.
Therapeutic Assessment and Pipeline Development Activities
The extensive therapeutic assessment covered in the report examines products by type, stage, route of administration, and molecule type. The pipeline development activities section delves into strategic collaborations and clinical trial advancements, offering a comprehensive view of emerging therapies poised to impact the treatment landscape.
Emerging Drugs and Clinical Advancements
Particularly noteworthy are several emerging drugs entering advanced clinical trial phases. Among them, candidates like CT053, Descartes-08, ALLO-501A, CTX110, and IMPT 314 are generating significant attention for their innovative approaches to targeting refractory and relapsed malignancies, as well as auto-immune diseases. The report showcases therapies that have been granted key designations, such as Fast Track and Regenerative Medicine Advanced Therapy (RMAT), by regulatory agencies, underscoring their potential to address unmet medical needs.
Comprehensive Coverage
The report provides a global perspective on the CAR-T therapy pipeline. It includes an analysis of inactive pipeline products and a detailed examination of therapies currently under development. The breadth and depth of this analysis offer a crucial resource for stakeholders across the healthcare and biotechnology industries.
A selection of companies mentioned in this report includes, but is not limited to:
- CARsgen
- CASI Pharmaceuticals
- Tessa Therapeutics
- Cartesian Therapeutics
- Gracell Bio
- Aurora BioPharma
- Carsgen Therapeutics
- Autolus Limited
- CRISPR Therapeutics
- Allogene Therapeutics
- Verismo Therapeutics
- Arcellx
- Nexcella
- JW Therapeutics
- Janssen Pharmaceuticals
- Chongqing Precision Biotech
- CoImmune, Inc.
- Mustang Bio
- Novartis Pharmaceuticals
- Shanghai Unicar-Therapy Bio-medicine Technology
- Sotio Biotech Inc.
- Beam Therapeutics
- AbCLon
- Nanjing IASO Biotherapeutics
- Autolus
- Beijing Immunochina Medical Science and Technology
- Carsgen Therapeutics
- Orgenesis
- IN8Bio
- Oxford BioMedica
For more information about this report visit https://www.researchandmarkets.com/r/z942g9
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
